Background: Chronic heart failure is a major health problem for prevalence, morbidity and costs; heart failure management programs may prevent hospital admissions, improve clinical status and reduce medical costs.
Methods: A care program for chronic heart failure patients was activated by the Cardiology Department, based on a nurse-monitored outpatient clinic, ran in cooperation with cardiologists, who were responsible for optimal pharmacological treatment. Nurses provided patient education, monitoring of clinical status and symptoms and verified adherence to pharmacologic and dietary therapy. To assess the impact of the program on hospitalization rate, functional status and quality of life we compared: 1) hospital admission rate for heart failure in the 6 months before and the 6 months after referral; 2) Minnesota Living with Heart Failure Questionnaire (MLHFQ) score and NYHA functional class at referral time and after 6 months. A cost-based analysis was performed to compare the two periods.
Results: Between January 1999 and November 2000, 107 patients were followed up for at least 6 months. Hospitalization declined by 70% (57 admissions in the 6 months before referral, 17 in the 6 months afterwards, p = 0.0001). Functional status improved after 6 months: 41 patients were in NYHA class III-IV at referral time, 26 after 6 months. The mean total score of MLHFQ was reduced from 33.9 to 28.7 (p = 0.005). The average cost of the program was estimated to be [symbol: see text] 218 (Itl 423,000) per patient in 6 months. The savings in overall cost of care was [symbol: see text] 615 (Itl 1,192,000) per patient in 6 months.
Conclusions: A management program based on a nurse-monitored outpatient clinic can reduce hospitalization rate, improve functional status and quality of life and decrease medical costs for chronic heart failure patient's care.
Download full-text PDF |
Source |
---|
J Transl Med
January 2025
Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, No. 4 Bei Jing Road, Yunyan District, Guiyang, 550004, Guizhou, China.
Background: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in the treatment of lymphoma for providing a more valuable reference for clinicians.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Statistics, Borana University, Borena, Oromia Region, Ethiopia.
Introduction: Hypertension is among the most significant non-communicable public health issues worldwide. High blood pressure, or hypertension, has been associated with severe health consequences, including death, aneurysms, stroke, chronic renal disease, eye damage, heart attack, heart failure, peripheral artery disease, and vascular dementia. Consequently, this study aimed to investigate the predictors linked to survival time and the progression of blood pressure measurements in hypertensive patients.
View Article and Find Full Text PDFActa Pharmacol Sin
January 2025
National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Sorting nexins (SNXs) as the key regulators of sorting cargo proteins are involved in diverse diseases. SNXs can form the specific reverse vesicle transport complex (SNXs-retromer) with vacuolar protein sortings (VPSs) to sort and modulate recovery and degradation of cargo proteins. Our previous study has shown that SNX3-retromer promotes both STAT3 activation and nuclear translocation in cardiomyocytes, suggesting that SNX3 might be a critical regulator in the heart.
View Article and Find Full Text PDFTransplant Proc
January 2025
Department of Cardiology, Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario Central de Asturias, Oviedo, Spain; Health Research Institute of Asturias, ISPA, Oviedo, Spain.
Introduction: Real-life data on the long-term use of a maintenance immunosuppressive protocol in heart transplant patients using delayed Everolimus + Tacrolimus are scarce.
Methods: This is a retrospective study that included all heart transplant patients from 2011 to 2021 in two Spanish hospitals. In Hospital A, the preferred immunosuppressive strategy included Everolimus initiation at 2 months post-transplant combined with Tacrolimus and was compared with the results of Hospital B, where a standard Tacrolimus and Mycophenolate mofetil protocol was used.
Eur J Intern Med
January 2025
Cardiology Department, Hospital Clínico Universitario, Universitat de València, INCLIVA, Valencia, Spain; CIBER Cardiovascular, Madrid, Spain.
Aims: Hypoalbuminemia is frequently found in patients with heart failure (HF), associated with higher morbimortality in acute HF (AHF). Moreover, Carbohydrate Antigen 125 (CA125) is elevated in most of the AHF patients. In this cohort of patients admitted for AHF, our objective was to evaluate the association between hypoalbuminemia and long-term outcomes, including mortality and HF readmissions, stratified by CA125 concentration.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!